Drugs / Recombinant Human Thymosin Beta 4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07586865 | May 2026 → Aug 2027 expected | ST-elevation myocardial infarction | Beijing Northland Biotech. Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Thymosin Beta 4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586865 ↗ |
| Known as | NL005 | “NL005 is a sterile solution of recombinant human thymosin beta 4 formulated for intravenous injection.” NCT07586865 ↗ |
| Modality | Protein / enzyme biologic | “NL005 is a sterile solution of recombinant human thymosin beta 4 formulated for intravenous injection.” NCT07586865 ↗ |
| Route | Intravenous | “administered as a slow intravenous bolus over approximately 3 minutes” NCT07586865 ↗ |